Phase 1, Febuxostat XR Relative Bioavailability Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets

NCT06233162

Healthy Subjects

NOT_YET_RECRUITING PHASE1

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

NCT05051553

Healthy Volunteers

COMPLETED PHASE1

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

NCT03112148

Healthy

COMPLETED PHASE1

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

NCT01731327

Healthy

COMPLETED PHASE1

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

NCT03722823

Hepatic Impairment

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested is this study is febuxostat XR. Four different formulations of febuxostat XR are being tested to see how the drug moves through the body. This study will look at safety and side effects in people who take febuxostat XR.

This cross-over study will enroll approximately 78 patients. Participants will be randomly assigned to 1of 4 sequences which will determine the order of the 4 treatments received:

* Febuxostat XR 80 mg capsule Formulation 1
* Febuxostat XR 80 mg capsule Formulation 2
* Febuxostat XR 80 mg capsule Formulation 3
* Febuxostat XR 80 mg capsule Formulation 4

Participants will take 1 dose on Day 1 with a washout period between each period.

This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 80 days. Participants will make multiple visits to the clinic including a period of confinement, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Sequence ABDC

Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).

Group Type EXPERIMENTAL

Febuxostat XR 80 mg Capsule F1

Intervention Type DRUG

Febuxostat extended-release (XR) capsules formulation 1

Febuxostat XR 80 mg Capsule F2

Intervention Type DRUG

Febuxostat XR capsules formulation 2

Febuxostat XR 80 mg Capsule F3

Intervention Type DRUG

Febuxostat XR capsules formulation 3

Febuxostat XR 80 mg Capsule F4

Intervention Type DRUG

Febuxostat XR capsules formulation 4

Treatment Sequence DACB

Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).

Group Type EXPERIMENTAL

Febuxostat XR 80 mg Capsule F1

Intervention Type DRUG

Febuxostat extended-release (XR) capsules formulation 1

Febuxostat XR 80 mg Capsule F2

Intervention Type DRUG

Febuxostat XR capsules formulation 2

Febuxostat XR 80 mg Capsule F3

Intervention Type DRUG

Febuxostat XR capsules formulation 3

Febuxostat XR 80 mg Capsule F4

Intervention Type DRUG

Febuxostat XR capsules formulation 4

Treatment Sequence CDBA

Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).

Group Type EXPERIMENTAL

Febuxostat XR 80 mg Capsule F1

Intervention Type DRUG

Febuxostat extended-release (XR) capsules formulation 1

Febuxostat XR 80 mg Capsule F2

Intervention Type DRUG

Febuxostat XR capsules formulation 2

Febuxostat XR 80 mg Capsule F3

Intervention Type DRUG

Febuxostat XR capsules formulation 3

Febuxostat XR 80 mg Capsule F4

Intervention Type DRUG

Febuxostat XR capsules formulation 4

Treatment Sequence BCAD

Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).

Group Type EXPERIMENTAL

Febuxostat XR 80 mg Capsule F1

Intervention Type DRUG

Febuxostat extended-release (XR) capsules formulation 1

Febuxostat XR 80 mg Capsule F2

Intervention Type DRUG

Febuxostat XR capsules formulation 2

Febuxostat XR 80 mg Capsule F3

Intervention Type DRUG

Febuxostat XR capsules formulation 3

Febuxostat XR 80 mg Capsule F4

Intervention Type DRUG

Febuxostat XR capsules formulation 4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Febuxostat XR 80 mg Capsule F1

Febuxostat extended-release (XR) capsules formulation 1

Intervention Type DRUG

Febuxostat XR 80 mg Capsule F2

Febuxostat XR capsules formulation 2

Intervention Type DRUG

Febuxostat XR 80 mg Capsule F3

Febuxostat XR capsules formulation 3

Intervention Type DRUG

Febuxostat XR 80 mg Capsule F4

Febuxostat XR capsules formulation 4

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations.
3. Is a healthy male or female and aged 18 to 55 years, inclusive, at the time of informed consent and first study medication dose.
4. Weighs at least 50.0 kg and has a body mass index (BMI) from 18.0 to 30.0 kg/m2, inclusive at Screening.
5. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
6. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent,
7. Is willing to refrain from strenuous exercise from Day -1 of Period 1 until Study Exit (Day 3 of Period 4).
8. Has estimated glomerular filtration rate (eGFR) ≥90 mL/min at Screening and Check-in (Day -1 of Period 1).

Exclusion Criteria

1. Has received any investigational compound within 30 days prior to the first dose of study medication.
2. Has received febuxostat in a previous clinical study or as a therapeutic agent.
3. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in the conduct of this study.
4. Has uncontrolled, clinically significant (CS) disease or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.
5. Has a known hypersensitivity to any component of the formulation of XO inhibitors, xanthine compounds, caffeine, or any component of the formulation of febuxostat capsules.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes